Abstract 3395
Background
The usefulness of re-sentinel node biopsy (re-SNB) is unclear in the management of patients with ipsilateral recurrent breast cancer.
Methods
We retrospectively reviewed 52 patients with locally recurrent breast cancer who underwent re-SNB from July 2012 to March 2019. Both radioactive colloid and indocyanine green were used in all cases.
Results
Forty-four patients were after SNB and 8 were after axillary lymph node dissection(ALND). SLNs were successfully visualized by lymphoscintigraphy in 94.2% (49/52) of cases (95.4% post-SNB vs. 87.5% post-ALND, Fisher’s exact test, p = 0.401). Among post-SNB patients with successful mapping, 50% had SLNs only in ipsilateral axilla(I) and 50% had at least one SLN in other regions(contralateral axilla [C] and/or parasternal region [P])with or without SLN in (I), compared to 28.6% and 71.4% in post-ALND cases respectively(p = 0.424). Among post-SNB cases with prior breast irradiation (n = 37), 44.4% had SLN only in (I) and 55.6% had at least one SLN in other regions, compared to 83.3% and 16.7% in cases without prior irradiation (n = 7) (p = 0.184), respectively. While these differences were not significant, a lower rate of visualization and higher frequency of aberrant lymphatic flow in post-ALND than those in post-SNB was noted, and prior irradiation might affect lymphatic flow. We tried re-SNB for 47 cases and SLNs were successfully removed in 45 (95.7%) patients (92.8% in post-SNB, 100% in post-ALND). Re-SNB for (I) was performed for all cases with hot spots in (I) and one case without hot spot. Re-SNB for (C) or (P) were decided based on physician’s judgment. The SLN identification rates by site were 92.1% (35/38) for (I), 90.0% (9/10) for (C), and 100% (3/3) for (P). Sentinel node metastasis was found in three cases, all of which were in (I). ALND was performed in one case with macrometastasis but was omitted in two cases with micrometastases. The median follow-up duration after re-SNB was 22 months and no recurrence was observed.
Conclusions
Sentinel node identification was possible with high detection rates among patients with recurrent breast cancer after prior breast-conserving and axillary surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Yamanaka: Honoraria (self): Chugai; Honoraria (self): Eisai; Honoraria (self): Novartis Pharma; Honoraria (self): Taiho; Honoraria (self): Phizer Japan. T. Yamashita: Honoraria (self), Research grant / Funding (institution): Chugai; Honoraria (self): Eisai; Honoraria (self): Novartis Pharma; Honoraria (self): Taiho; Honoraria (self), Research grant / Funding (institution): Nippon Kayaku; Honoraria (self): AstraZeneca; Honoraria (self), Research grant / Funding (institution): Kyowa kirin; Honoraria (self): Phizer Japan; Honoraria (self): Takeda. N. Suganuma: Honoraria (self): Eisai; Honoraria (self): Novartis Pharma; Honoraria (self): Taiho; Honoraria (self): Kyowa kirin; Honoraria (self): Phizer Japan. All other authors have declared no conflicts of interest.
Resources from the same session
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract
3353 - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Presenter: Jalid Sehouli
Session: Poster Display session 2
Resources:
Abstract